A
References
Aboody, K. S., J. Najbauer, M. Z. Metz, M. D’Apuzzo, M. Gutova, A. J. Annala, T. W. Synold, L. A. Couture, S. Blanchard, R. A. Moats, E. Garcia, S. Aramburo, V. V. Valenzuela, R. T. Frank, M. E. Barish, C. E. Brown, S. U. Kim, B. Badie, and J. Portnow. 2013. Neural stem cell–mediated enzyme/prodrug therapy for glioma: Preclinical studies. Science Translational Medicine 5(184):184ra59.
Alzheimer’s Association. 2014. 2014 Alzheimer’s disease facts and figures. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 10(2).
Bardy, G. H., K. L. Lee, D. B. Mark, J. E. Poole, D. L. Packer, R. Boineau, M. Domanski, C. Troutman, J. Anderson, G. Johnson, S. E. McNulty, N. Clapp-Channing, L. D. Davidson-Ray, E. S. Fraulo, D. P. Fishbein, R. M. Luceri, J. H. Ip, for the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Sudden Cardiac Death in Heart Failure Trial. 2005. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. New England Journal of Medicine 352(3):225-237.
Barkham, M., J. Connell, W. B. Stiles, J. N. Miles, F. Margison, C. Evans, and J. Mellor-Clark. 2006. Dose−effect relations and responsive regulation of treatment duration: The good enough level. Journal of Consulting and Clinical Psychology 74(1):160-167.
Baumgart, M., H. M. Snyder, M. C. Carrillo, S. Fazio, H. Kim, and H. Johns. 2015. Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population-based perspective. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 11(6):718-726.
Berry, S. M., J. T. Connor, and R. J. Lewis. 2015. The platform trial: An efficient strategy for evaluating multiple treatments. The Journal of the American Medical Association 313(16):1619-1620.
Calcoen, D., L. Elias, and X. Yu. 2015. What does it take to produce a breakthrough drug? Nature Reviews Drug Discovery 14(3):161-162.
Chang, K. D., K. Dienes, C. Blasey, N. Adleman, T. Ketter, and H. Steiner. 2003. Divalproex monotherapy in the treatment of bipolar offspring with mood and behavioral disorders and at least mild affective symptoms. The Journal of Clinical Psychiatry 64(8):936-942.
Chang, K., N. E. Adleman, K. Dienes, D. I. Simeonova, V. Menon, and A. Reiss. 2004. Anomalous prefrontal-subcortical activation in familial pediatric bipolar disorder: A functional magnetic resonance imaging investigation. Archives of General Psychiatry 61(8):781-792.
DeRubeis, R. J., Z. D. Cohen, N. R. Forand, J. C. Fournier, L. A. Gelfand, and L. Lorenzo-Luaces. 2014. The personalized advantage index: Translating research on prediction into individualized treatment recommendations. A demonstration. PLoS ONE 9(1):e83875.
DVBIC (Defense and Veterans Brain Injury Center). 2016. DoD worldwide numbers for TBI.http://www.dvbic.org/dod-worldwide-numbers-tbi (accessed July 20, 2016).
Findling, R. L., T. W. Frazier, E. A. Youngstrom, N. K. McNamara, R. J. Stansbrey, B. L. Gracious, M. D. Reed, C. A. Demeter, and J. R. Calabrese. 2007. Double-blind, placebo-controlled trial of divalproex monotherapy in the treatment of symptomatic youth at high risk for developing bipolar disorder. The Journal of Clinical Psychiatry 68(5):781-788.
Garrett, A. S., D. J. Miklowitz, M. E. Howe, M. K. Singh, T. K. Acquaye, C. G. Hawkey, G. H. Glover, A. L. Reiss, and K. D. Chang. 2015. Changes in brain activation following psychotherapy for youth with mood dysregulation at familial risk for bipolar disorder. Progress in Neuro-Psychopharmacology & Biological Psychiatry 56:215-220.
Gash, D. M., Z. Zhang, and G. Gerhardt. 1998. Neuroprotective and neurorestorative properties of GDNF. Annals of Neurology 44(3 Suppl 1):S121-S125.
Gimenez, F., M. T. Krauze, F. Valles, P. Hadaczek, J. Bringas, N. Sharma, J. Forsayeth, and K. S. Bankiewicz. 2011. Image-guided convection-enhanced delivery of GDNF protein into monkey putamen. Neuroimage 54(Suppl 1):S189-S195.
Government Publishing Office. Code of Federal Reulations. Title 21, Volume 1. https://www.gpo.gov/fdsys/pkg/CFR-2012-title21-vol1/pdf/CFR-2012-title21-vol1-part3.pdf (accessed October 25, 2016).
Hendrix, J. A., R. J. Bateman, H. R. Brashear, C. Duggan, M. C. Carrillo, L. J. Bain, R. DeMattos, R. G. Katz, S. Ostrowitzki, E. Siemers, R. Sperling, and O. V. Vitolo. 2016. Challenges, solutions, and recommendations for Alzheimer’s disease combination therapy. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 12(5):623-630.
Hieronymus, F., J. F. Emilsson, S. Nilsson, and E. Eriksson. 2016. Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression. Molecular Psychiatry 21(4):523-530.
Hildebrand, K. R., D. D. Elsberry, and S. J. Hassenbusch. 2003. Stability and compatibility of morphine-clonidine admixtures in an implantable infusion system. Journal of Pain and Symptom Management 25(5):464-471.
Holtzman, D. M., J. C. Morris, and A. M. Goate. 2011. Alzheimer’s disease: The challenge of the second century. Science Translational Medicine 3(77):77sr71.
Howard, K. I., S. M. Kopta, M. S. Krause, and D. E. Orlinsky. 1986. The dose−effect relationship in psychotherapy. The American Psychologist 41(2):159-164.
IOM (Institute of Medicine). 2013. Best care at lower cost: The path to continuously learning health care in America. Washington, DC: The National Academies Press.
Komanski, C. B., R. L. Rauck, J. M. North, K. S. Hong, R. D’Angelo, and K. R. Hildebrand. 2015. Intrathecal clonidine via lumbar puncture decreases blood pressure in patients with poorly controlled hypertension. Neuromodulation 18(6):499-507; discussion 507.
Kuehn, B. M. 2006. Industry, FDA warm to “adaptive” trials. The Journal of the American Medical Association 296(16):1955-1957.
Lin, L. F., D. H. Doherty, J. D. Lile, S. Bektesh, and F. Collins. 1993. GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260(5111):1130-1132.
Luber, B., and S. H. Lisanby. 2014. Enhancement of human cognitive performance using transcranial magnetic stimulation (TMS). Neuroimage 85(Pt 3):961-970.
Luber, B., L. H. Kinnunen, B. C. Rakitin, R. Ellsasser, Y. Stern, and S. H. Lisanby. 2007. Facilitation of performance in a working memory task with rTMS stimulation of the precuneus: Frequency- and time-dependent effects. Brain Research 1128(1):120-129.
Luber, B., A. D. Stanford, P. Bulow, T. Nguyen, B. C. Rakitin, C. Habeck, R. Basner, Y. Stern, and S. H. Lisanby. 2008. Remediation of sleep-deprivation−induced working memory impairment with fMRI-guided transcranial magnetic stimulation. Cerebral Cortex 18(9):2077-2085.
Luber, B., J. Steffener, A. Tucker, C. Habeck, A. V. Peterchev, Z. D. Deng, R. C. Basner, Y. Stern, and S. H. Lisanby. 2013. Extended remediation of sleep deprived-induced working memory deficits using fMRI-guided transcranial magnetic stimulation. Sleep 36(6):857-871.
Lutz, W., S. G. Hofmann, J. Rubel, J. F. Boswell, M. K. Shear, J. M. Gorman, S. W. Woods, and D. H. Barlow. 2014. Patterns of early change and their relationship to outcome and early treatment termination in patients with panic disorder. Journal of Consulting and Clinical Psychology 82(2):287-297.
Lutz, W., J. Rubel, A. K. Schiefele, D. Zimmermann, J. R. Bohnke, and W. W. Wittmann. 2015. Feedback and therapist effects in the context of treatment outcome and treatment length. Psychotherapy Research: Journal of the Society for Psychotherapy Research 25(6):647-660.
Meurer, W. J., R. J. Lewis, and D. A. Berry. 2012. Adaptive clinical trials: A partial remedy for the therapeutic misconception? The Journal of the American Medical Association 307(22):2377-2378.
Morrell, M. J., and C. Halpern. 2016. Responsive direct brain stimulation for epilepsy. Neurosurgery Clinics of North America 27(1):111-121.
NASEM (National Academies of Sciences, Engineering, and Medicine). 2015. Non-invasive neuromodulation of the central nervous system: Opportunities and challenges: Workshop summary. Washington, DC: The National Academies Press.
Ngandu, T., J. Lehtisalo, A. Solomon, E. Levalahti, S. Ahtiluoto, R. Antikainen, L. Backman, T. Hanninen, A. Jula, T. Laatikainen, J. Lindstrom, F. Mangialasche, T. Paajanen, S. Pajala, M. Peltonen, R. Rauramaa, A. Stigsdotter-Neely, T. Strandberg, J. Tuomilehto, H. Soininen, and M. Kivipelto. 2015. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): A randomised controlled trial. Lancet 385(9984):2255-2263.
Nishino, I., N. Carrillo-Carrasco, and Z. Argov. 2015. GNE myopathy: Current update and future therapy. Journal of Neurology, Neurosurgery, and Psychiatry 86(4):385-392.
Patel, N. K., M. Bunnage, P. Plaha, C. N. Svendsen, P. Heywood, and S. S. Gill. 2005. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: A two-year outcome study. Annals of Neurology 57(2):298-302.
Perlis, R. H., S. Miyahara, L. B. Marangell, S. R. Wisniewski, M. Ostacher, M. P. DelBello, C. L. Bowden, G. S. Sachs, A. A. Nierenberg, and STEP-BD Investigators. 2004. Long-term implications of early onset in bipolar disorder: Data from the first 1000 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Biological Psychiatry 55(9):875-881.
Peterchev, A. V., T. A. Wagner, P. C. Miranda, M. A. Nitsche, W. Paulus, S. H. Lisanby, A. Pascual-Leone, and M. Bikson. 2012. Fundamentals of transcranial electric and magnetic stimulation dose: Definition, selection, and reporting practices. Brain Stimulation 5(4):435-453.
Prince, M., R. Bryce, E. Albanese, A. Wimo, W. Ribeiro, and C. P. Ferri. 2013. The global prevalence of dementia: A systematic review and metaanalysis. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 9(1):63-75.
Ridding, M. C., and J. L. Taylor. 2001. Mechanisms of motor-evoked potential facilitation following prolonged dual peripheral and central stimulation in humans. The Journal of Physiology 537(Pt 2):623-631.
Rubel, J., W. Lutz, S. M. Kopta, K. Kock, T. Minami, D. Zimmermann, and S. M. Saunders. 2015. Defining early positive response to psychotherapy: An empirical comparison between clinically significant change criteria and growth mixture modeling. Psychological Assessment 27(2):478-488.
Sperling, R. A., C. R. Jack, Jr., S. E. Black, M. P. Frosch, S. M. Greenberg, B. T. Hyman, P. Scheltens, M. C. Carrillo, W. Thies, M. M. Bednar, R. S. Black, H. R. Brashear, M. Grundman, E. R. Siemers, H. H. Feldman, and R. J. Schindler. 2011. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 7(4):367-385.
Sperling, R., E. Mormino, and K. Johnson. 2014. The evolution of preclinical Alzheimer’s disease: Implications for prevention trials. Neuron 84(3):608-622.
Stulz, N., W. Lutz, S. M. Kopta, T. Minami, and S. M. Saunders. 2013. Dose−effect relationship in routine outpatient psychotherapy: Does treatment duration matter? Journal of Counseling Psychology 60(4):593-600.
van Lutterveld, R., and J. A. Brewer. 2015. Neurofeedback from the posterior-cingulate cortex as a mental mirror for meditation. Biofeedback 43(3):117-120.
Yaksh, T. L., S. Hassenbusch, K. Burchiel, K. R. Hildebrand, L. M. Page, and R. J. Coffey. 2002. Inflammatory masses associated with intrathecal drug infusion: A review of preclinical evidence and human data. Pain Medicine 3(4):300-312.
